Compare NTST & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | GLUE |
|---|---|---|
| Founded | 2019 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2020 | 2021 |
| Metric | NTST | GLUE |
|---|---|---|
| Price | $20.26 | $16.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 4 |
| Target Price | $21.15 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 1.6M | 776.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | ★ 150.00 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $195,006,000.00 | $75,622,000.00 |
| Revenue This Year | $15.47 | $84.02 |
| Revenue Next Year | $14.57 | N/A |
| P/E Ratio | $252.38 | ★ $72.42 |
| Revenue Growth | ★ 19.79 | N/A |
| 52 Week Low | $14.00 | $3.50 |
| 52 Week High | $21.30 | $25.77 |
| Indicator | NTST | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 33.37 |
| Support Level | $17.67 | $14.51 |
| Resistance Level | $21.30 | $16.66 |
| Average True Range (ATR) | 0.40 | 1.02 |
| MACD | -0.14 | -0.19 |
| Stochastic Oscillator | 15.79 | 7.06 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.